CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers

Review Article2014 Mar;7(3):244-54.

JOURNAL:JACC Cardiovasc Interv. Article Link

Clinical impact of intravascular ultrasound guidance in drug-eluting stent implantation for unprotected left main coronary disease: pooled analysis at the patient-level of 4 registries

de la Torre Hernandez JM, Baz Alonso JA, IVUS-TRONCO-ICP Spanish study. Keywords: drug-eluting stent(s); IVUS; left main coronary artery

FULL TEXT PDF